NextCure

Photo of a final puzzle piece about to fit into a puzzle

Biotech

NextCure advances ADC pivot with $745M deal for phase 1 drug

NextCure has ramped up its ADC pivot, penning a $745 million deal for the ex-China rights to Simcere Zaiming’s phase 1-stage tumor asset.

James Waldron Jun 16, 2025 9:52am

poker all in chips go yes bet

NextCure stops programs to take ADC fight to Big Pharma trio

Nov 8, 2024 6:16am

target reach ladder climb meet win beat competition

NextCure jettisons mAB to focus on ADC aimed at same target

Dec 14, 2023 9:13am

partnership collaboration legal document

NextCure, LegoChem join big-league rivals in ADC race

Nov 16, 2022 9:40am

Missed target failed trial trial failure

NextCure discards antibody after candidate flunks phase 2 trial

Nov 4, 2022 9:10am